HUBEI PROVINCE, China, May 12 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today announced that it has appointed Jun Tang to its board of directors, effective May 1, 2008.
Mr. Tang has over a decade of experience in corporate management and strategic planning. He now serves as President and Chief Executive Officer at Xin Hua Du Industrial Group Co., a conglomerate with subsidiaries across many industries, including Zijin Mining Group (2899.HK; 601899.CH). Before joining Xin Hua Du, Mr. Tang served as President and Director of Shanda Interactive Entertainment Ltd. (Nasdaq GS: SNDA) from February 2004 through April 2008, and to this day remains on the Board of Directors as an advisor to the CEO. During his tenure at Shanda, Mr. Tang played a key role in leading the company from a small Shanghai-based online game company to a U.S.-listed Chinese media company. Between January 1998 and January 2004, Mr. Tang held several positions with Microsoft China Co., Ltd., including that of President from March 2002. Additionally, he received the Microsoft Chairman Bill Gates Award in 1998 and the Microsoft Top Honor Award in 2002 from Microsoft Corporation, and remains the Honorary President of Microsoft (China) Co. Ltd. In 1993, Mr. Tang founded Intertex Company, a software and entertainment company, in California. Mr. Tang received his doctorate, master's, and bachelor's degrees in the U.S., Japan and China, respectively.
"Mr. Tang is a proven professional manager with extensive experience leading domestic and international companies. We believe that Mr. Tang's unparalleled experience will be a great asset for Benda," said Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical.
Other current members of the board of directors include incumbent directors Q.Y. Ma, Eric Yu and Charles Mo. John Micek resigned from the Company's board of directors on April 25, 2008.
Mr. Wan continued, "We greatly appreciate Mr. Micek's dedication over the years, which has been invaluable to our growth. On behalf of the Company, I want to thank John for his many contributions to Benda, and for helping to lay a firm foundation for our future success. We wish him every success in all of his future endeavors."
About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.
Safe Harbor Statement
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
|SOURCE Benda Pharmaceutical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved